Streetbeat News

Stock Prices

ACN

The article discusses whether it is worth investing in Accenture (ACN) based on Wall Street's bullish views. It highlights the influence of analyst recommendations on stock prices and questions their significance.

Portfolio Pulse from

December 19, 2024 | 3:45 pm

WDAY

Wall Street analysts have given positive recommendations for Workday (WDAY), suggesting it as a good investment. Analyst ratings can influence stock prices, but their importance varies.

Portfolio Pulse from

December 19, 2024 | 3:45 pm

OC

Analysts' recommendations can significantly influence stock prices, as seen with Owens Corning (OC). Investors should consider these ratings when making investment decisions.

Portfolio Pulse from

December 19, 2024 | 3:45 pm

ENVX

Levi & Korsinsky has initiated an investigation into Enovix Corporation for potential violations of federal securities laws, following concerns about the timing of its $100 million public offering in early November.

Portfolio Pulse from

December 19, 2024 | 3:45 pm

SLG

SL Green (SLG) has experienced a significant decline of 11.17% over the past four weeks, leading to it being technically oversold. This suggests a potential exhaustion of selling pressure. Additionally, Wall Street analysts have been revising earnings estimates higher, indicating a possible trend reversal for SLG in the near term.

Portfolio Pulse from

December 19, 2024 | 3:45 pm

BOOM

Levi & Korsinsky has filed a securities class action lawsuit on behalf of DMC Global Inc. (NASDAQ:BOOM) shareholders. Investors who suffered losses can seek potential recovery under federal securities laws.

Portfolio Pulse from

December 19, 2024 | 3:45 pm

MOD

Wall Street analysts have given Modine (MOD) a 'Buy' rating, which could influence investor decisions and impact the stock's price.

Portfolio Pulse from

December 19, 2024 | 3:45 pm

EMN

Eastman Chemical (EMN) is recommended for retention in portfolios due to its innovation-driven growth strategy and effective cost-management actions, despite facing demand challenges in certain markets.

Portfolio Pulse from

December 19, 2024 | 3:45 pm

VRDN

Viridian Therapeutics reported positive phase 3 results for its drug veligrotug in treating chronic thyroid eye disease, aiming for a BLA filing in the second half of 2025. The company is also developing VRDN-003, with phase 3 data expected in early 2026, and has promising pipeline candidates VRDN-006 and VRDN-008.

Portfolio Pulse from

December 19, 2024 | 3:45 pm

NICE

Wall Street analysts are optimistic about NICE Ltd., which could influence investor decisions and impact the stock's price.

Portfolio Pulse from

December 19, 2024 | 3:45 pm